Advertisement
Singapore markets close in 1 hour 32 minutes

  • Straits Times Index

    3,403.46
    -7.35 (-0.22%)
     

  • Nikkei

    40,780.70
    -131.67 (-0.32%)
     

  • Hang Seng

    17,478.02
    -321.59 (-1.81%)
     

  • FTSE 100

    8,183.19
    -20.74 (-0.25%)
     

  • Bitcoin USD

    55,728.98
    -1,543.09 (-2.69%)
     

  • CMC Crypto 200

    1,154.25
    -11.87 (-1.02%)
     

  • S&P 500

    5,567.19
    +30.17 (+0.54%)
     

  • Dow

    39,375.87
    +67.87 (+0.17%)
     

  • Nasdaq

    18,352.76
    +164.46 (+0.90%)
     

  • Gold

    2,388.30
    -9.40 (-0.39%)
     

  • Crude Oil

    82.64
    -0.52 (-0.63%)
     

  • 10-Yr Bond

    4.2720
    -0.0830 (-1.91%)
     

  • FTSE Bursa Malaysia

    1,611.02
    -5.73 (-0.35%)
     

  • Jakarta Composite Index

    7,225.86
    -27.51 (-0.38%)
     

  • PSE Index

    6,529.43
    +36.68 (+0.56%)
     

Compared to Estimates, Bausch + Lomb (BLCO) Q4 Earnings: A Look at Key Metrics

Zacks Equity Research
·2-min read

Bausch + Lomb (BLCO) reported $1.17 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 17.8%. EPS of $0.24 for the same period compares to $0.23 a year ago.

The reported revenue represents a surprise of +7.50% over the Zacks Consensus Estimate of $1.09 billion. With the consensus EPS estimate being $0.17, the EPS surprise was +41.18%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

ADVERTISEMENT

Here is how Bausch + Lomb performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenue- Vision Care: $662 million versus the two-analyst average estimate of $636.56 million. The reported number represents a year-over-year change of +5.8%.

  • Revenue- Pharmaceuticals: $307 million versus the two-analyst average estimate of $262.42 million. The reported number represents a year-over-year change of +68.7%.

  • Product sales: $1.17 billion compared to the $1.08 billion average estimate based on two analysts. The reported number represents a change of +17.9% year over year.

  • Other revenues: $5 million compared to the $5 million average estimate based on two analysts. The reported number represents a change of 0% year over year.

  • Revenue- Surgical: $204 million versus the two-analyst average estimate of $192.27 million. The reported number represents a year-over-year change of +8.5%.

View all Key Company Metrics for Bausch + Lomb here>>>

Shares of Bausch + Lomb have returned +1% over the past month versus the Zacks S&P 500 composite's +3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Bausch + Lomb Corporation (BLCO) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research